Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Reed Business Information (RBI) was a prominent global provider of data, analytics, and business information services across diverse industries, including healthcare and life sciences. Operating as a division of the RELX Group, the company specialized in high-value data tools and workflow solutions that assisted professionals in making informed commercial decisions. Its portfolio included well-known brands such as ICIS for chemical markets and PharmaForce for pharmaceutical sales force effectiveness. In 2020, RELX retired the Reed Business Information brand, integrating its remaining business units into LexisNexis Risk Solutions to streamline its data-driven offerings. Although not a drug developer, RBI played a significant role in the healthcare ecosystem by providing market intelligence and strategic data to pharmaceutical companies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Reed Business Information.